Rapid Micro Biosystems (RPID) Amortization of Deferred Charges (2020 - 2026)

Rapid Micro Biosystems (RPID) reported Amortization of Deferred Charges of $86000.0 for Q1 2026, up 17.81% sequentially from $73000.0 in Q4 2025.

Rapid Micro Biosystems (RPID) Amortization of Deferred Charges (2020 - 2026) Analysis & Trends

Rapid Micro Biosystems (RPID) has 4 years of Amortization of Deferred Charges data on file, last reported at $86000.0 in Q1 2026.

For the quarter ending Q1 2026, Amortization of Deferred Charges changed N/A year-over-year to $86000.0; the trailing twelve-month figure through Mar 2026 stood at $159000.0 (changed N/A YoY), and the FY2025 full-year result was $97000.0, changed N/A from the prior year.
Amortization of Deferred Charges grew to $86000.0 in Q1 2026, from $73000.0 in the prior quarter.
In the past five years, Amortization of Deferred Charges ranged from a high of $86000.0 in Q1 2026 to a low of $73000.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	183.40 Bn	176.11 Bn	6.27 Bn
2	Stryker	128.93 Bn	126.05 Bn	3.81 Bn
3	Medtronic	108.35 Bn	99.13 Bn	6.41 Bn
4	Boston Scientific	68.71 Bn	67.25 Bn	3.61 Bn
5	Edwards Lifesciences	48.35 Bn	44.68 Bn	1.29 Bn
6	Dexcom	28.37 Bn	27.25 Bn	750.30 Mn
7	GE HealthCare Technologies	28.04 Bn	25.76 Bn	1.98 Bn
8	Smith & Nephew	26.90 Bn	26.33 Bn	-
9	Koninklijke Philips	24.06 Bn	20.93 Bn	2.07 Bn
10	Rapid Micro Biosystems	89.73 Mn	80.30 Mn	371,000.00

Download Data